Search results for: Market Access

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

7 January 2020

…third of these are ‘optimised’ recommendations. In this report we quantify the patient access associated with NICE ‘optimised’ recommendations. We evaluated optimised recommendations published between 2015 and 2019; 40 contained…

Altering the trajectory of HIV in Europe

22 May 2025

…access to care. Healthcare barriers: Limited access to testing and treatment in underserved groups, availability of medication, and healthcare provider biases contribute to gaps in testing and care. Policy and…

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

15 February 2023

…Published online June 2021. Accessed September 30, 2022. https://www.ace-hta.gov.sg/docs/default-source/process-methods/ace-drug-and-vaccine-evaluation-methods-and-process-guide-(june-2021).pdf Danish Medicines Council. The Danish Medicines Council Methods Guide For Assessing New Pharmaceuticals. Published online 2021. Accessed November 9, 2022. https://medicinraadet.dk/media/wq0dxny2/the_danish_medicines_council_methods_guide_for_assessing_new_pharmaceuticals_version_1-…

Claudio Jommi

19 April 2023

…Regolatorie e Market Access in Ambito Farmaceutico e Biotecnologico. He was Professor of Practice of Health Policy at SDA Bocconi School of Management, where he held the position of Director…

Around The World in HTAs: Egypt – The Road Ahead

31 July 2023

…facilitation of market access, and capacity and funding support. Making the process – and the resulting HTA reports- evidence-based and public once they are reviewed and finalized will be vital,…

Impact

…and therapies. Their research informs pricing decisions, market access strategies, and drug development priorities. Pharmaceutical companies collaborate with health economists to demonstrate the value of their products to payers and…

Three seminars forthcoming at OHE

12 May 2016

…of drugs, and how patent and price regulation regimes affect the speed of market access.  He will show that price regulation delays launch, while longer and more extensive patent rights…

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

8 January 2021

…the other way around”. From a patient advocate perspective, she considers pragmatic access models that allow combining timely access with evidence generation, and addressing optimal sequencing of therapies, to be…

The Market for Biosimilars

25 January 2011

This publication expands on the series of posts published earlier on this blog.   It reports on a seminar intended to encourage further thought about the distinguishing characteristics of the market…